The EMA’s Committee for Medicinal Products for Human Use (CHMP) backed eight new medicines in its September recommendations, including two ovarian cancer therapies and a potential first oral option for hidradenitis suppurativa. The set also included additional approvals and label expansions referenced in the CHMP package. While CHMP opinions are not final national approvals, they typically drive next steps with regulators across the EU and can influence pricing and reimbursement timelines. The brief indicates continued diversity across oncology and inflammatory disease categories. For companies with programs under CHMP review, the main takeaway is a clear regulatory pathway through European assessment in September, with oral-inflammation options standing out as a new commercial theme.